Study to Evaluate Safety and Immunogenicity of COVID-19 Vaccine in Children 6 Months to < 12 Years
NCT05468736
Recruiting
This is a Phase 2/3 randomized, observer-blinded, placebo-controlled, age de-escalation trial to evaluate the safety and immunogenicity of 2 primary doses and a booster dose of NVX CoV2373 given 21 days apart in pediatric participants (3 age cohorts; 6 to < 12 years, 2 to < 6 years, and 6 to < 24 months of age). Each age cohort will be conducted in 2 parts starting with the oldest age cohort (6 to < 12 years of age).
Gender:
All
Ages:
Between 6 months and 11 years
Locations: PanAmerican Clinical Research, Brownsville, Texas +62 locations
Conditions: COVID-19
Register for Updates
Study of Obeldesivir in Nonhospitalized Participants With COVID-19
NCT05715528
Recruiting
The goal of this clinical study is to test if obeldesivir (formerly GS-5245) is safe and effective for the treatment of coronavirus disease 2019 (COVID-19) in participants who have a standard risk of developing severe illness. This study will also measure how much obeldesivir gets into the blood and how long it takes for the body to get rid of it.
Gender:
All
Ages:
Between 12 years and 64 years
Locations: PanAmerican Clinical Research, Brownsville, Texas +142 locations
Conditions: COVID-19
Register for Updates
A Study of mRNA-1283.222 Injection Compared With mRNA-1273.222 Injection in Participants ≥12 Years of Age to Prevent COVID-19
NCT05815498
Recruiting
The purpose of this study is to evaluate the safety, reactogenicity, and relative vaccine efficacy (rVE) of the mRNA-1283.222 vaccine as well as its immunogenicity in comparison to the mRNA-1273.222 vaccine.
Gender:
All
Ages:
12 years and above
Locations: PanAmerican Clinical Research, LLC, Brownsville, Texas +215 locations
Conditions: COVID-19
Register for Updates
A Study to Learn About a Repeat 5-Day Treatment With the Study Medicines (Called Nirmatrelvir/Ritonavir) in People 12 Years Old or Older With Return of COVID-19 Symptoms and SARS-CoV-2 Positivity After Finishing Treatment With Nirmatrelvir/Ritonavir
NCT05567952
Recruiting
The purpose of this study is to learn about the safety and effects of nirmatrelvir/ritonavir for the potential treatment of COVID-19 rebound. The study is seeking participants who: Have completed treatment with nirmatrelvir/ritonavir Have a rebound in COVID-19 symptoms Are SARS-CoV-2 (COVID-19) positive All study medications will be taken 2 times a day by mouth for 5 days. The first dose of study medication is taken at the study clinic and the rest at home. We will examine the experiences of... Read More
Gender:
All
Ages:
12 years and above
Locations: Headlands Research - Brownsville, Brownsville, Texas +68 locations
Conditions: COVID-19
Register for Updates
PROSPECTIVE OPEN LABEL CLINICAL TRIAL TO ADMINISTER A BOOSTER DOSE OF PFIZER/BIONTECH OR MODERNA COVID-19 VACCINE IN HIGH-RISK INDIVIDUALS
NCT05279365
Recruiting
The recent rise in infections with the Omicron variant of the SARS-CoV-2 is alarming. Equally disconcerting is the fact that individuals who were previously vaccinated (< 6 months) and have co-morbidities that are considered high risk, are getting re-infected...a process referred to as "breakthrough". There is some evidence that in these high risk individuals, the gradual decrease in immunity against the virus as depicted by a drop in anti-SARS-CoV-2 antibodies, is responsible (partially or whol... Read More
Gender:
All
Ages:
18 years and above
Locations: Brownsville Independent School District, Brownsville, Texas +3 locations
Conditions: SARS CoV 2 Infection, COVID-19
Register for Updates